HPV subtypes and immunological parameters of cervical cancer in Iceland during two time periods, 1958-1960 and 1995-1996

Gynecologic Oncology

Volumn 89, Issue 1, 2003, Pages 22-30

  Mikaelsdottir, Evgenia K ^a   Benediktsdottir, Kristrun R ^b   Olafsdottir, Kristrun ^b   Arnadottir, Thorgerdur ^c   Ragnarsson, Gunnar B ^b   Olafsson, Karl ^a   Sigurdsson, Kristjan ^b   Kristjansdottir, Gudny S ^a   Imsland, Albert K ^d   Ögmundsdottir, Helga M ^a,b   Rafnar, Thorunn ^d,e  

^a ICELANDIC CANCER SOCIETY   (Iceland)

^b LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^c UNIVERSITY OF ICELAND   (Iceland)

^d DECODE GENETICS   (Iceland)

^e Icelandic Genomics Corporation   (Iceland)

Author keywords

Apoptosis; Cervical cancer; Fas; Fas ligand; HLA class I; HPV; Iceland; p53

Indexed keywords

FAS ANTIGEN; FAS LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN P53;

ADENOSQUAMOUS CARCINOMA; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER DIAGNOSIS; CANCER IMMUNOLOGY; CANCER SCREENING; CARCINOGENICITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; ICELAND; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEXUAL BEHAVIOR; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CARCINOMA; WART VIRUS;

EID: 0345269971     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00053-2     Document Type: Article

References (39)

1. Munoz N. Human papillomavirus and cancer the epidemiological evidence . J Clin Virol. 19:2000;1-5.
2. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., Snijders P.J., Peto J., Meijer C.J., Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 189:1999;12-19.
3. zur Hausen H. Papillomaviruses causing cancer evasion from host-cell control in early events in carcinogenesis . J Natl Cancer Inst. 92:2000;690-698.
4. Anttila T., Saikku P., Koskela P., Bloigu A., Dillner J., Ikaheimo I., Jellum E., Lehtinen M., Lenner P., Hakulinen T., Narvanen A., Pukkala E., Thoresen S., Youngman L., Paavonen J. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. J Am Med Assoc. 285:2001;47-51.
5. Murthy N.S., Mathew A. Risk factors for pre-cancerous lesions of the cervix. Eur J Cancer Prev. 9:2000;5-14.
6. Beskow A.H., Josefsson A.M., Gyllensten U.B. HLA class II alleles associated with infection by HPV16 in cervical cancer in situ. Int J Cancer. 93:2001;817-822.
7. Konya J., Dillner J. Immunity to oncogenic human papillomaviruses. Adv Cancer Res. 82:2001;205-238.
8. Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French L.E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J., Tschopp J. Melanoma cell expression of Fas(Apo-1/CD95) ligand implications for tumor immune escape . Science. 274:1996;1363-1366.
9. Strand S., Hofmann W.J., Hug H., Muller M., Otto G., Strand D., Mariani S.M., Stremmel W., Krammer P.H., Galle P.R. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med. 2:1996;1361-1366.
10. Restifo N.P. Countering the 'counterattack' hypothesis. Nature Med. 7:2001;259.
11. Ragnarsson G.B., Mikaelsdottir E.K., Vidarsson H., Jonasson J.G., Olafsdottir K., Kristjansdottir K., Kjartansson J., Ogmundsdottir H.M., Rafnar T. Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells. Br J Cancer. 83:2000;1715-1721.
12. Contreras D.N., Krammer P.H., Potkul R.K., Bu P., Rossi J.L., Kaufmann A.M., Gissmann L., Qiao L. Cervical cancer cells induce apoptosis of cytotoxic T lymphocytes. J Immunother. 23:2000;67-74.
13. Fisher C.J., Gillett C.E., Vojtesek B., Barnes D.M., Millis R.R. Problems with p53 immunohistochemical staining the effect of fixation and variation in the methods of evaluation . Br J Cancer. 69:1994;26-31.
14. Wright D.K., Manos M. Sample preparation from paraffin-embedded tissues. Innis MA G.D., Sninsky J.J., White T.J. PCR protocols- a guide to methods and applications. 1990;153-158 Academic Press, San Diego.
15. Baay MF Q.W., Koudstaal J., Hollema H., Duk J.M., Burger M.P., Stolz E., Herbrink P. Comprehensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol. 34:1996;745-747.
16. de Roda Husman AM W.J., van den Brule A.J., Meijer C.J., Snijders P.J. The use of general primers GP5 and GP6 elongated at their 3′ ends with highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol. 76:1995;1057-1062.
17. Tieben LM tS.J., Minnaar R.P., Bouwes Bavinck J.N., Berkhout R.J., Vermeer B.J., Jebbink M.F., Smits H.L. Detection of cutaneous and genital HPV types in clinical samples by PCR using consensus primers. J Virol Methods. 42:1993;265-280.
18. Statsoft. Statistica user's guide, version 5.0. Tulsa, OK: StatSoft Inc., 2000.
19. S-Plus. S-Plus. Guide to statistics. Seattle, WA: MathSoft, 2000.
20. Zar J. Biostatistical analysis. 1984;Prentice-Hall, New York.
21. Brown MB F.A. Robust tests for the equality of variances. J Am Statist Assoc. 69:1974;364-367.
22. Johnson RA W.D. Applied multivariate statistical analysis. 1992;Prentice-Hall, New York.
23. Scheffé H. The analysis of variance. 1959;J Wiley, New York.
24. Hintze J. PASS users guide. Kaysville, UT: NCSS, 1996.
25. Sigurdsson K., Hrafnkelsson J., Geirsson G., Gudmundsson J., Salvarsdottir A. Screening as a prognostic factor in cervical cancer analysis of survival and prognostic factors based on Icelandic population data, 1964-1988 . Gynecol Oncol. 43:1991;64-70.
26. Sigurdsson K. Effect of organized screening on the risk of cervical cancer. Evaluation of screening activity in Iceland, 1964-1991. Int J Cancer. 54:1993;563-570.
27. Vizcaino A.P., Moreno V., Bosch F.X., Munoz N., Barros-Dios X.M., Parkin D.M. International trends in the incidence of cervical cancer I. Adenocarcinoma and adenosquamous cell carcinomas . Int J Cancer. 75:1998;536-545.
28. Chamberlain J. Reasons that some screening programmes fail to control cervical cancer. In: Hakama MMA, Day NE, editors. Screening for cancer of the uterine cervix. Lyon: IARC Sci. Publ., 1986; Vol. 76, p. 161-8.
29. Sigurdsson K. The Icelandic and Nordic cervical screening programs trends in incidence and mortality rates through 1995 . Acta Obstet Gynecol Scand. 78:1999;478-485.
30. Nagai Y., Maehama T., Asato T., Kanazawa K. Detection of human papillomavirus DNA in primary and metastatic lesions of carcinoma of the cervix in women from Okinawa, Japan. Am J Clin Oncol. 24:2001;160-166.
31. Riethdorf S., Riethdorf L., Milde-Langosch K., Park J.W., Loning T. Differences in HPV 16- and HPV 18 E6/E7 oncogene expression between in situ and invasive adenocarcinomas of the cervix uteri. Virchows Arch. 437:2000;491-500.
32. van Muyden R.C., ter Harmsel B.W., Smedts F.M., Hermans J., Kuijpers J.C., Raikhlin N.T., Petrov S., Lebedev A., Ramaekers F.C., Trimbos J.B., Kleter B., Quint W.G. Detection and typing of human papillomavirus in cervical carcinomas in Russian women a prognostic study . Cancer. 85:1999;2011-2016.
33. Breitburd F., Ramoz N., Salmon J., Orth G. HLA control in the progression of human papillomavirus infections. Semin Cancer Biol. 7:1996;359-371.
34. Lee SH S.M., Park W.S., Kim S.Y., Dong S.M., Lee H.K., Park J.Y., Oh R.R., Jang J.J., Lee J.Y., Yoo N.J. Immunohistochemical analysis of Fas ligand expression in normal human tissues. APMIS. 107:1999;1013-1019.
35. Aguilar-Lemarroy A., Kirchhoff S., Whitaker N., Gariglio P., zur Hausen H., Krammer P.H., Rosl F. Differential sensitivity of human papillomavirus type 16(+) and type 18(+) cervical carcinoma cells to CD95-mediated apoptosis. Int J Cancer. 93:2001;823-831.
36. Abd El All H., Rye A., Duvillard P. p53 immunohistochemical expression of Egyptian cervical carcinoma. Pathol Oncol Res. 5:1999;280-284.
37. Ngan H.Y., Cheung A.N., Liu S.S., Cheng D.K., Ng T.Y., Wong L.C. Abnormal expression of pan-ras, c-myc and tp53 in squamous cell carcinoma of cervix correlation with HPV and prognosis . Oncol Rep. 8:2001;557-561.
38. Horn L.C., Fischer U., Hanel C., Kuhn H., Raptis G., Bilek K. p53 in surgically treated and pathologically staged cervical cancer correlation with local tumor progression, but not with lymphatic spread . Pathol Res Pract. 197:2001;605-609.
39. Valgardsdottir R., Tryggvadottir L., Steinarsdottir M., Olafsdottir K., Jonasdottir S., Jonasson J.G., Ogmundsdottir H.M., Eyfjord J.E. Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis. APMIS. 105:1997;121-130.